Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.83 -3.37%

-$0.34 today

Market cap
$189.33M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.77M

Average 0.48M

Returns on capital

Artiva Biotherapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-76.3%

avg 16.5%

ROIC

-74.9%

avg -43.7%

ROA

-64.0%

avg -38.0%

Analysis

ROA is currently the strongest return metric at -64.0% versus its period average of -38.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Fred Aslan

CEO, Principal Financial & Accounting Officer and DirectorUSD 1.22M511.46M5.90%

Jennifer Kinsbruner Bush

Chief Operating OfficerUSD 839.21K51——

Christopher Horan

Chief Technical Operations OfficerUSD 777.62K59302.32K1.22%

Peter Flynn

Co-Founder & Strategic AdvisorUSD 499.37K52——

Gines Diego Miralles

President and Head of Research & DevelopmentUSD 55K64122.50K0.50%

David Moriarty

Senior Vice President of Clinical Operations————

Heather Raymon

Senior Vice President of Research & Early Development—61148.23K0.60%

Nicholas Veomett

Vice President of Corporate Development————

Andrew Cronauer

VP, General Counsel & Corporate Secretary————

Benjamin Dewees

Senior Vice President of Regulatory Affairs————

Feng Xu

Senior Vice President of Biometrics————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 2, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

23

$109.18M

Sells

22

$2.84M

Net Transaction Value

+$106.34M

Net buying

Most Active

RA CAPITAL MANAGEMENT, L.P.

21 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 2, 26

Horan Christopher

Direct

Sell$43.6K
Nov 2, 26

Bush Jennifer

Direct

Sell$35.3K
Nov 2, 26

Banerjee Subhashis

Direct

Sell$4.6K
Nov 2, 26

Aslan Fred

Direct

Sell$260K
Oct 6, 26

Aslan Fred

Direct

Sell$168.9K
Oct 5, 26

Horan Christopher

Direct

Sell$70.7K
Oct 5, 26

Bush Jennifer

Direct

Sell$57.2K
Oct 5, 26

Banerjee Subhashis

Direct

Sell$7.5K
Oct 5, 26

Aslan Fred

Direct

Sell$421.8K
Sep 8, 26

Aslan Fred

Direct

Sell$255.7K

1–10 of 45

Summary

Insiders reported 23 buys worth $109.18M and 22 sells worth $2.84M over the last 12 months. That adds up to net buying of $106.34M. RA CAPITAL MANAGEMENT, L.P. was the most active insider with 21 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Artiva Biotherapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ARTV's management, answered from reported figures.

Who manages ARTV?

Artiva Biotherapeutics, Inc. (ARTV) lists 11 active executives. The top listed executive is David Moriarty, Senior Vice President of Clinical Operations.

Are ARTV insiders buying or selling?

Recent insider activity shows net buying of $2.17T.